SEC
REGN icon

Seven Eight Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Seven Eight Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,993
Closed -$4.2M – 501
2024
Q3 		$4.2M Buy
+3,993
New +$4.44M 0.38% 43
2024
Q1 		– Sell
-4,557
Closed -$4M – 777
2023
Q4 		$4M Buy
4,557
+3,582
+367% +$2.95M 0.46% 50
2023
Q3 		$802K Buy
+975
New +$766K 0.09% 296
2023
Q2 		– Sell
-4,294
Closed -$3.53M – 629
2023
Q1 		$3.53M Buy
+4,294
New +$3.24M 0.74% 24
2019
Q4 		– Sell
-15,900
Closed -$4.41M – 746
2019
Q3 		$4.41M Buy
+15,900
New +$4.71M 0.23% 124

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seven Eight Capital's REGN Position: Q4 2024 in Review

Seven Eight Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 3,993 shares — an estimated $4.2M sold.

Seven Eight Capital first reported a position in REGN in Q3 2019 and held it in 5 quarters. The position peaked at $4.41M in Q3 2019. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Seven Eight Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 3,993 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $4.2M.
  • Seven Eight Capital first reported a position in Regeneron Pharmaceuticals in Q3 2019 and held it in 5 quarters.
  • Seven Eight Capital's Regeneron Pharmaceuticals position peaked at $4.41M in Q3 2019.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.